Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in brazil;Custo-efetividade do anastrozol em comparação com tamoxifeno no tratamento adjuvante do câncer de mama precoce no Brasil

Revista da Associacao Medica Brasileira

Volumn 55, Issue 4, 2009, Pages 410-415

  Fonseca, Marcelo ^a   Araújo, Gabriela T B ^b   Saad, Everardo D ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Axia Bio Consultoria Econômica   (Brazil)

^c Dendrix Research   (Brazil)

Author keywords

Anastrozole; Aromatase inhibitors; Breast neoplasms; Cost benefit analysis; Delphi technique; Markov chains; Tamoxifen

Indexed keywords

EID: 70450199062     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302009000400015     Document Type: Article

References (39)

1. Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2006: Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2005.
2. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727-41.
3. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-4.
4. Leung GM, Thach TQ, Chan E, Foo W, Meng O, Fielding R, et al. Short-term, medium-term, long-term, and lifetime risks of developing and dying of breast carcinoma in a Westernized Chinese population: Evidence from Hong Kong between 1976 and 2000. Cancer. 2005;103:501-8.
5. Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer. 1980;42:635-44.
6. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27.
7. Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994:7-14.
8. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists Collaborative Group. N Engl J Med. 1988;319:1681-92.
9. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11:111-25.
10. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-9.
11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005;365:60-2.
12. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-57.
13. Revistakairos.com [Internet site]. [citado 25 set 2005]. São Paulo: Kairos; 2005. Disponível em: http://www.revistakairos.com/revista/bra/default_bra.asp.
14. Calcmed Tabelas: tabelas convênios [computer software]. Version 1.17. São Paul: Visual Line Design; 2001.
15. Revista Simpro Hospitalar. 2005;7(38).
16. Brasil. Ministério da Saúde. Rede Interagencial de Informações para a Saúde. [citado 20 abr 2006]. Disponível em: http://tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2003/a08.def.
17. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. In: Mallarkey G. Economic Evaluation in Healthcare. Hong Kong: Adis International, 1999. p.103.
18. Le MG, Arriagada R, Spielmann M, Guinebretière JM, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002;94:2813-20.
19. Willner J, Kiricuta IC, Kolbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys. 1997;37:853-63.
20. Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006;106:35-41.
21. Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol. 2000;18:1696-708.
22. Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2001;51:74-80.
23. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol. 2002;20:2713-25.
24. Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat. 1997;45:181-92.
25. Haycox A et Bagust A. Pharmacoeconomics and clinical trials. In Walley T, Haycox A, Boland A. Pharmacoeconomics.Spain: Elsevier Science Limited; 2004. p.127-40.
26. International Society for Pharmacoeconomics and Outcomes Research. Task Forces - Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report [text in Internet]. Lawrenceville: ISPOR; 2008 [cited in 2008 oct 8] Available at: http://www.ispor.org/councils/documents/MSEconTransTFFinalReport.pdf
27. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.
28. World Health Organization. WHO commission on macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health. Geneva: World health Organization; 2001
29. Brasil. Instituto Brasileiro de Geografia e Estatística (IBGE). Contas nacionais trimestrais - Indicadores de volume e valores correntes. [citado 27 abr 2006]. Disponível em: http://www.ibge.gov.br/home/presidencia/noticias/noticia_visualiza.php?i d_noticia=337&id_pagina=1.
30. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004;101:1311-22.
31. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
32. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat. 2007;106(2):229-38.
33. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer. 2006;14:917-27.
34. Piskur P, Sonc M, Cufer T, Borstnar S, Mrhar A. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. Anticancer Drugs. 2006;17:719-24.
35. Moeremans K, Annemans L. Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer. 2006;16(Suppl 2):576-8.
36. Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat. 2007;101:325-33.
37. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial. Br J Cancer. 2007;97:152-61.
38. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H, et al. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol. 1999;10:385-390.
39. Brasil. Instituto Brasileiro de Geografia e Estatística (IBGE).Tábuas completas de mortalidade. [citado 14 maio 2007]. Disponível em: http://www.ibge.gov.br/home/estatistica/populacao/tabuadevida/2005/defau lttab.shtm.